Seattle Genetics signs $4.4bn worth oncology deals with Merck

pharmanewsdaily- September 14, 2020 0

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More

AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

pharmanewsdaily- July 27, 2020 0

AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter's DS-1062, a ... Read More

Olema Oncology raises $54m for breast cancer drug candidate OP-1250

pharmanewsdaily- July 23, 2020 0

Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women's cancers, has raised $54 million in a Series B financing round, which ... Read More

Genetron Health’s semiconductor-based NGS system gets Chinese approval

pharmanewsdaily- December 30, 2019 0

Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the ... Read More

GE Healthcare unveils Serena Bright mammography solution for biopsy

pharmanewsdaily- December 3, 2019 0

GE Healthcare has unveiled new Serena Bright, a contrast-enhanced mammography solution for biopsy, which is claimed to help clinicians to detect breast cancer patients in ... Read More

Pharma giants bag Lynparza EMA approval for metastatic breast cancer

pharmanewsdaily- May 19, 2019 0

Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency's (EMA) approval for their poly ADP-ribose polymerase ... Read More

Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC

pharmanewsdaily- May 5, 2019 0

Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab ... Read More

Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

pharmanewsdaily- April 17, 2019 0

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover ... Read More

Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials

pharmanewsdaily- December 9, 2018 0

Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with endocrine therapy, has demonstrated substantial efficacy in ... Read More

Oncternal Therapeutics launches Phase 1b trial of Cirmtuzumab in combination with Paclitaxel in breast cancer

pharmanewsdaily- September 13, 2018 0

Oncternal Therapeutics, a leading U.S. oncology company, has announced the dosing of the first patient in a phase 1b trial of its investigational drug cirmtuzumab, ... Read More